title: [Comparative evaluation of the hemodynamic effect of 6% hydroxyethyl starch 130/0.42 solution versus 4% modified liquid gelatin solution in cardiosurgical patients].
abstract: The study included 20 patients who underwent a 6% HES 130/0.42 (venofundin, B-Braun) infusion test. A 4% MLG (gelofusine, B-Braun) infusion test was carried out in 16 patients. The baseline hemodynamic parameters did not differ before infusion of the compared solutions. In the HES 130 group, the mean cardiac index (CI) increase of 23% was observed in 9 cases; its reduction was seen in 7 cases. In the MLG group, the mean CI increase of 26% was noted in 14 patients and its decrease was in 10. With increased CI in response to the venofundin test infusion, there were statistically significant increases in central blood volume (CBV) by 14.6%, global end-diastolic volume (GEDV) by 13%, right atrial pressure (RAP) by 50%, and pulmonary artery wedge pressure (PAWP) by 35.5%. In the increased CI group, gelofusine caused statistically significant increases in CBV by 19%, GEDV by 7%, RAP by 33%, and PAWP by 29%. When CI was decreased in the use of MLG, there were statistically significant increases in CBV by 20%, GEDV by 17%, RAP by 49%, and PAWP by 20.5%. HES 130/0.4 resulted in increases in CBV by 18%, GEDV by 16.6%, RAP by 80%, and PAWP by 43%. 6% HES 130/0.42 and 4% MLG in doses of 500 ml had a similar hemodynamic effect in the infusion test during 30 min. Volume load with the test colloid solutions allows the functional reserves of the cardiovascular system to be estimated in cardiosurgical patients. Inotropic drugs are indicated for patients with lower cardiac output and infusion therapy is performed in those with considerably increased CI.
authors.forename: A A
authors.initials: AA
authors.lastname: Eremenko
authors.forename: P N
authors.initials: PN
authors.lastname: Safarov
mesh_terms: D006348:Cardiac Surgical Procedures; D005260:Female; D005780:Gelatin / Q000008:administration & dosage* / Q000494:pharmacology; D006438:Hemodilution / Q000379:methods*; D006439:Hemodynamics / Q000187:drug effects*; D006801:Humans; D006895:Hydroxyethyl Starch Derivatives / Q000008:administration & dosage* / Q000494:pharmacology; D008297:Male; D008875:Middle Aged; D010952:Plasma Substitutes / Q000008:administration & dosage* / Q000494:pharmacology
chemical_list: D006895:Hydroxyethyl Starch Derivatives; D010952:Plasma Substitutes; C025916:modified fluid gelatins; D005780:Gelatin